<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>503</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15501783</PubmedId>
            <Abstract>We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-microg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-microg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>6519-27</ArticlePages>
            <ArticleTitle>Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Nardin</LastName>
                    <ForeName>Elizabeth H</ForeName>
                </Author>
                <Author>
                    <LastName>Oliveira</LastName>
                    <ForeName>Giane A</ForeName>
                </Author>
                <Author>
                    <LastName>Calvo-Calle</LastName>
                    <ForeName>J Mauricio</ForeName>
                </Author>
                <Author>
                    <LastName>Wetzel</LastName>
                    <ForeName>Kristiane</ForeName>
                </Author>
                <Author>
                    <LastName>Maier</LastName>
                    <ForeName>Carolin</ForeName>
                </Author>
                <Author>
                    <LastName>Birkett</LastName>
                    <ForeName>Ashley J</ForeName>
                </Author>
                <Author>
                    <LastName>Sarpotdar</LastName>
                    <ForeName>Pramod</ForeName>
                </Author>
                <Author>
                    <LastName>Corado</LastName>
                    <ForeName>Michael L</ForeName>
                </Author>
                <Author>
                    <LastName>Thornton</LastName>
                    <ForeName>George B</ForeName>
                </Author>
                <Author>
                    <LastName>Schmidt</LastName>
                    <ForeName>Annette</ForeName>
                </Author>
            </Authors>
            <Affiliations>New York University School of Medicine, Department of Medical and Molecular Parasitology, 341 East 25th St., New York, NY 10010, USA. nardie01@med.nyu.edu.</Affiliations>
            <ArticleChemicalList>Alum Compounds;Antibodies, Protozoan;Epitopes;Hepatitis B Core Antigens;Malaria Vaccines;Protozoan Proteins;Vaccines, Synthetic;circumsporozoite protein, Protozoan;aluminum sulfate;Interferon-gamma</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adolescent; Adult; Alum Compounds; Amino Acid Sequence; Animals; Antibodies, Protozoan(blood); Double-Blind Method; Epitopes; Hepatitis B(genetics; immunology; metabolism); Hepatitis B Core Antigens(genetics; metabolism); Humans; Interferon-gamma(metabolism); Malaria Vaccines(administration &amp; dosage; adverse effects; immunology); Malaria, Falciparum(immunology; parasitology; prevention &amp; control); Middle Aged; Molecular Sequence Data; Plasmodium falciparum(immunology); Protozoan Proteins(chemistry; genetics; immunology; metabolism); T-Lymphocytes(immunology); Vaccines, Synthetic(administration &amp; dosage; adverse effects; immunology); Virion(genetics; immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>72</Volume>
                <Issue>11</Issue>
                <Title>Infection and immunity</Title>
                <Issn>0019-9567</Issn>
                <MedlineTa>Infect Immun</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>T*</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EYLNKIQNSLSTEWSPCSVT</LinearSequence>
                        <StartingPosition>318</StartingPosition>
                        <EndingPosition>337</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P19597.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5843</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Figure 1</LocationOfData>
                <EpitopeId>15056</EpitopeId>
                <ReferenceStartingPosition>318</ReferenceStartingPosition>
                <ReferenceEndingPosition>337</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The authors note that the T* epitope ellicits strong Th1-type CD4+ T cells and is presented by a broad range of HLA class II molecules.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>3617</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                                <GeoLocId>http://purl.obolibrary.org/obo/GAZ_00000464</GeoLocId>
                                <Age>Adults</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <DiseaseState>ONTIE:0003423</DiseaseState>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EYLNKIQNSLSTEWSPCSVT</LinearSequence>
                                            <StartingPosition>318</StartingPosition>
                                            <EndingPosition>337</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P19597.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5843</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>T*</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Alum (Aluminum hydroxide gel)</Adjuvant>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>0.5-ml injection of 50 Î¼g ICC-1132 (Malarivax) into deltoid muscle on days 0, 56, and 168.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>T cell</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>EYLNKIQNSLSTEWSPCSVT</LinearSequence>
                                            <StartingPosition>318</StartingPosition>
                                            <EndingPosition>337</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P19597.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5843</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>The recombinant protein (Malarivax vaccine) was designated ICC-1132.  The protein product injected contained HBV core protein (Truncated HBc gene aa 1-149).  Fused between D78 and P79 of HBc were the T1 and B epitopes.  The universal T* epitope was fused near the C-terminus of HBc following V149.  The T* epitope replaces residues 150-183 of the HBc protamine domain.  Sequence for B epitope is (NANPNANPNANP) and the sequence for T1 is NANPNVDPNANP.  All three epitopes (B, T1, and T*) are derived from P. falciparum CS protein. .</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele/>
                        <Antigen>
                            <AntigenReferenceName>T*</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EYLNKIQNSLSTEWSPCSVT</LinearSequence>
                                        <StartingPosition>318</StartingPosition>
                                        <EndingPosition>337</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P19597.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5843</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

